Healthcare Simulation in Higher Education

Growth opportunities for payers in different segments and regions. The competitive state of the Medicare Advantage market heading into 2022.

In this on-demand webinar, we take a closer look at two key trends currently reshaping our industry: consumerism and digitization. We’ll discuss how providers can capitalize on these trends to simultaneously improve patient satisfaction and cash flow.

As written, however, EKRA is far more expansive with its broad language enabling the federal government to monitor provider arrangements intended to generate business for any laboratory services, not just those related to individuals in treatment for substance abuse disorders, payable by a FHCP or commercial health insurer.

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.